Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 9

See more details

Referenced in 51 patents
52 readers on Mendeley
  • Article usage
  • Citations to this article (108)

Advertisement

Research Article Free access | 10.1172/JCI116278

Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion.

L Ferradini, A Mackensen, C Genevée, J Bosq, P Duvillard, M F Avril, and T Hercend

Laboratoire d'Hémato-Immunologie, Institut National de la Santé et de la Recherche Médicale U333, Villejuif, France.

Find articles by Ferradini, L. in: PubMed | Google Scholar

Laboratoire d'Hémato-Immunologie, Institut National de la Santé et de la Recherche Médicale U333, Villejuif, France.

Find articles by Mackensen, A. in: PubMed | Google Scholar

Laboratoire d'Hémato-Immunologie, Institut National de la Santé et de la Recherche Médicale U333, Villejuif, France.

Find articles by Genevée, C. in: PubMed | Google Scholar

Laboratoire d'Hémato-Immunologie, Institut National de la Santé et de la Recherche Médicale U333, Villejuif, France.

Find articles by Bosq, J. in: PubMed | Google Scholar

Laboratoire d'Hémato-Immunologie, Institut National de la Santé et de la Recherche Médicale U333, Villejuif, France.

Find articles by Duvillard, P. in: PubMed | Google Scholar

Laboratoire d'Hémato-Immunologie, Institut National de la Santé et de la Recherche Médicale U333, Villejuif, France.

Find articles by Avril, M. in: PubMed | Google Scholar

Laboratoire d'Hémato-Immunologie, Institut National de la Santé et de la Recherche Médicale U333, Villejuif, France.

Find articles by Hercend, T. in: PubMed | Google Scholar

Published March 1, 1993 - More info

Published in Volume 91, Issue 3 on March 1, 1993
J Clin Invest. 1993;91(3):1183–1190. https://doi.org/10.1172/JCI116278.
© 1993 The American Society for Clinical Investigation
Published March 1, 1993 - Version history
View PDF
Abstract

Malignant melanomas are often infiltrated by T lymphocytes. It is postulated that the presence of tumor-infiltrating lymphocytes (TIL) reflects ongoing immune responses against transformed cells. Such "responses" appear generally inefficient with the potential exception of infrequent clinical situations characterized by spontaneous tumor regression. We have characterized here the molecular structure of the T cell receptor beta chain expressed by TILs in a case of regressive melanoma. Advantage was taken of the PCR technology to study T lymphocytes directly without cell culture. Experimentally validated V beta subfamily specific primers were used to evaluate the V beta usage in TILs and control samples. Our results reveal that clonal T cell populations, precisely defined by their V-D-J junctional sequences, are amplified at the tumor site. The existence of such local antigen-driven selections support the hypothesis that antitumor responses may indeed take place in regressive melanoma.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1183
page 1183
icon of scanned page 1184
page 1184
icon of scanned page 1185
page 1185
icon of scanned page 1186
page 1186
icon of scanned page 1187
page 1187
icon of scanned page 1188
page 1188
icon of scanned page 1189
page 1189
icon of scanned page 1190
page 1190
Version history
  • Version 1 (March 1, 1993): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 9
  • Article usage
  • Citations to this article (108)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 51 patents
52 readers on Mendeley
See more details